Affiliation:
1. Internal Medicine Department, October 6 University, Giza, Egypt
2. Internal Medicine Department, Al-Azhar University, Cairo, Egypt
3. Internal Medicine Department, Al-Azhar University, Damietta, Egypt
4. Internal Medicine Department, Beni-Suef University, Beni-Suef, Egypt
Abstract
Erythropoietin (EPO) resistance is frequently reported in hemodialysis (HD) patients. Metabolic syndrome (MetS) is a common biochemical condition that comprises central obesity, dyslipidemia, hypertension, and hyperglycemia. The present study aimed to assess the relation between MetS and EPO resistance in HD patients. The present multicentric study included 150 patients with EPO resistance and 150 patients without EPO resistance. Short-acting EPO resistance was diagnosed if the erythropoietin resistance index is ≥1.0 IU/kg/gHb. Comparison between patients with EPO resistance and patients without resistance revealed that the former group had significantly higher body mass index, lower hemoglobin levels, lower albumin levels, higher ferritin levels, and higher high-sensitivity C-reactive protein (hsCRP) levels. In addition, patients in the EPO resistance group had significantly higher frequency of MetS (75.3% vs 38.0%, p < 0.001) and higher number of MetS components (2.7 ± 1.3 vs 1.8 ± 1.6, p < 0.001). Multivariate logistic regression analysis identified lower albumin levels (OR (95% CI): 0.072 (0.016–0.313), p < 0.001), higher ferritin levels (OR (95% CI): 1.05 (1.033–1.066), p< 0.001), higher hsCRP levels (OR (95% CI): 1.041 (1.007–1.077), p = 0.018), and MetS (OR (95% CI): 36.68 (2.893–465.05), p = 0.005) as predictors of EPO resistance in the studied patients. The present study identified MetS as a predictor of EPO resistance in HD patients. Other predictors include serum ferritin, hsCRP, and albumin levels.
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine